TVP-SOLAR
27.1.2022 15:20:05 CET | Business Wire | Press release
PepsiCo, one of the largest food and beverage companies in the world, implemented an innovative project in its Sete Lagoas (MG) snacks operation: a solar thermal plant that captures sunlight and converts it into thermal energy for heating process water. Through this technology, it was possible to reduce natural gas consumption by 140’000 m³ in the unit - which will also reduce greenhouse gas (GHG) emissions by almost 280 tons . This number is equivalent to the planting of almost 18’000 trees.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005027/en/
The thermo-solar plant is made up of high-vacuum solar thermal flat panels, running automatically, without supervision and without the need for cleaning. The first results show that the plant generated about 3.9 kWh/m²/day of thermal energy during the summer months, providing hot water at 60-75°C, even in the dry climate of Sete Lagoas. The energy targets were hit. The water heated by the system is used in several factory processes. “To give an example, we use the water heated by the thermo solar system to cook the corn in our snacks. The difference is that the water is already heated to the process, so we have to use less flame time to reach the temperature we use at this stage of production” , describes Bruno Guerreiro, Sustainability Manager at PepsiCo Brazil.
With the new solar thermal plant, PepsiCo moves towards its global goal of reducing carbon emissions by 40% by 2030 (2015 baseline) and Net-zero by 2040. “It is an important innovation to use thermal energy from the solar plant in the country. With this initiative, we became more sustainable, a premise that is at the heart of the way we do business at the company, continually seeking to evolve towards a Positive Value Chain” , explained Guerreiro. According to him, the solution is scalable and should be implemented in other PepsiCo Brazil plants in the coming years, with even larger areas of solar panels.
The solar thermal plant at the Sete Lagoas site is the result of a partnership between PepsiCo and TVP Solar, a Swiss company specializing in solar thermal technology with state-of-the-art solutions. TVP Solar designs, develops, manufactures and markets high vacuum, mirrorless solar thermal collectors based on patented technology. Solar thermal energy is carbon-free and a cheaper alternative than that generated by liquid fuels.
Piero Abbate, CEO of TVP Solar, highlights that the partnership with PepsiCo is emblematic for the company, because it highlights the importance of solar thermal energy for the food and beverage industry. “We hope this will be the beginning of a long-term collaboration with PepsiCo,” says Piero.
In 2021, PepsiCo announced the launch of the PepsiCo Positive (pep+) platform, which puts sustainability at the heart of how the company creates growth and value, operating within the limits of the planet and inspiring positive change for the environment and people. As a result, sustainability starts to guide the way PepsiCo operates its business: from sourcing ingredients, manufacturing and selling its products in a more sustainable way, to inspiring people to make choices that are better for themselves and the planet. “Our solar thermal plant is another step on our journey towards sustainability. We are constantly evolving in our processes and innovating on several fronts to do our part to contain climate change, reducing greenhouse gas (GHG) emissions throughout our value chain” , said the CEO of PepsiCo Brasil Alimentos, Alex Carretero .
To learn more about the PepsiCo Positive agenda, visit
https://www.pepsico.com.br/sustentabilidade/pepsicopositive .
About PepsiCo
PepsiCo products are enjoyed more than a billion times a day by consumers in more than 200 countries and territories worldwide. PepsiCo generated more than $70 billion in global net revenue in 2020, driven by a complementary food and beverage portfolio that, in Brazil, includes PEPSI®, GATORADE®, QUAKER®, LAY'S®, DORITOS®, RUFFLES®, CHEETOS ®, KERO COCO®, H2OH!®, TODDY® among others. PepsiCo's product portfolio includes a broad range of food and beverage products, including 23 brands that generate more than $1 billion each in estimated annual sales.
PepsiCo is guided by the vision of Being the Global Leader in Convenient Food and Beverages by Winning with Purpose, which reflects our drive to win sustainably in the marketplace and embed purpose in all aspects of the business. For more information, visit www.pepsico.com.br .
About TVP Solar :
TVP Solar SA is a Swiss company which designs, develops, manufactures and markets innovative high-vacuum solar thermal collectors based on patented technology. TVP revolutionized solar thermal, decarbonizing industrial processes in large-scale deployments. TVP has been installed across 9 countries and 3 continents, supplying carbon-free renewable heat, the cheapest thermal energy cutting OPEX and CO2 emissions, while securing energy supply. For more information please visit: www.tvpsolar.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005027/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom